Asian Stocks Rise as Softer U.S. Inflation Boosts Sentiment Despite Middle East Tensions 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
SpaceX Aborts Starship Test Flight as Engine Issue Delays Launch 
South Korea Raises Interest Rates to 2.75% as Inflation and Weak Won Drive Tightening 
Asian Stocks Rally as Cooling U.S. Inflation Boosts Fed Rate Cut Hopes 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Brazil Weighs IP Curbs, Patent Suspensions After New U.S. Tariffs 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Moonshot Launches Kimi K3, China's Largest Open-Source AI Model 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
China Home Prices Fall Again in June Despite Slower Pace of Decline 
Port of Los Angeles Posts Record June Cargo Volume as Importers Rush Ahead of U.S. Tariffs 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Dollar Slides as Softer US Inflation Dims Fed Rate Hike Expectations 
Oil Prices Set for Weekly Surge as U.S.-Iran Conflict Fuels Supply Fears 
NTSB Leads Investigation Into Ryanair Boeing 737 Engine Failure Over Greece 
Mizuho has unveiled its January US Top Picks, spotlighting Chewy, GE Vernova, Enliven Therapeutics, Quest Diagnostics, DuPont, and Salesforce. These companies align with Mizuho’s high-conviction investment ideas, driven by expected catalysts over the next year.
Chewy earned a spot for its strong EBITDA margin expansion, supported by automation, vet-focused initiatives, and app engagement. With a $42 price target, analysts see a 17% upside for the pet retailer.
GE Vernova stands out as a key player in power generation, providing turbines and grid equipment that supply 30% of global electricity. Mizuho forecasts significant growth in natural gas power contracts by 2025, driven by rising data center demand.
Enliven Therapeutics shows promise with ELVN-001, an investigational tyrosine kinase inhibitor (TKI) demonstrating early efficacy in chronic myeloid leukemia (CML). Analysts see potential for ELVN-001 to expand into first-line treatment, bolstering its market outlook.
Quest Diagnostics appeals for its stable cash flow and growth opportunities in diagnostics, underpinned by Medicare and commercial pricing strength. Mizuho highlights its acquisition pipeline and EPS growth forecast for 2025.
DuPont’s planned split into ElectronicsCo, WaterCo, and the new DuPont is seen as a value catalyst. Analysts cite the company’s leadership in specialty materials like Kevlar and Tyvek, alongside seasonal sales recovery and electronics growth.
Salesforce rounds out the list, with Data Cloud and Agentforce technology driving productivity and revenue growth. Upcoming updates, multi-cloud deals, and margin improvements position Salesforce for continued success in digital transformation.
These additions reflect Mizuho’s strategic outlook for 2024, showcasing diverse opportunities across industries.
